Multicentre Double-blinded, Randomized Placebo-controlled Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2018
At a glance
- Drugs Arimoclomol (Primary)
- Indications Gaucher's disease type I; Gaucher's disease type III
- Focus Proof of concept; Therapeutic Use
- Sponsors Orphazyme
- 26 Jun 2018 According to an Orphazyme media release,Status changed from planning to recruiting.
- 21 Jun 2018 According to an Orphazyme media release, first patient has received the first dose. And Results from the Phase II trial are expected in H1 2019.
- 29 May 2018 According to an Orphazyme media release, company is expected to enroll first patient in Q2 2018.